We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hemoglobin A1c Preferred to Glucose for Diabetes Diagnosis

By LabMedica International staff writers
Posted on 27 Jul 2009
Print article
Hemoglobin A1c (HbA1c) was an accepted and reliable measure of long-term glycemic control in diabetics, whereas glucose has been the "gold standard” for diabetes diagnosis. Chemical societies and laboratories have to deal with a surprising recommendation to measure HbA1c rather than glucose for diagnosis of diabetes.

The new recommendation was discussed at the American Association for Clinical Chemistry's (AACC) 2009 annual meeting, which was held in Chicago, IL, (USA) from July 19-23, 2009. A seminar at the meeting focused on the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) criteria for screening and diagnosing diabetes; the ADA criteria for diagnosing diabetes in pregnant women; and the use of handheld glucose meters in intensive care unit (ICU) patients.

Dr. David B. Sacks, from Brigham and Women's Hospital (Boston, MA, USA), reported that the new recommendation to measure HbA1c rather than glucose for diagnosis of diabetes is a major departure from all prior guidelines. He said, "Although the specific details of the recommendations to be proposed by these bodies have not been decided, it appears highly likely that all of the major clinical diabetes organizations will adopt HbA1c measurement for the diagnosis of diabetes.”

Related Links:

Brigham and Women's Hospital


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.